What's trending in cardiometabolic medicine — and what's coming next.
The HORIZON trial didn't kill the Lp(a) hypothesis — it reminded us how far preventive cardiology has come. When background therapy is this good, proving incremental benefit requires rethinking how we design trials, who we enroll, and what "success" means.
Read the full article →
PBMs, rebate walls, and the trillion-dollar middlemen standing between patients and affordable medication. The first installment of our “Why Healthcare Costs So Much” series pulls back the curtain on the drug pricing pipeline.
Read article →
Compounded semaglutide, BPC-157, and "research peptides" are flooding gyms, med spas, and social media. The FDA is cracking down, Novo Nordisk is suing, and patients are caught in the middle.
Read article →
The most studied supplement in sports nutrition, held to a real evidentiary standard. What creatine actually does for muscle, brain, and metabolic health — and what your doctor needs to know about your labs.
Read article →
The "Not a Single Drop" doctrine has dominated headlines — but the evidence tells a more nuanced story. We dissect the J-curve debate and what moderate wine consumption actually does for your heart.
Read article →Chicago. Late-breaking trials, new guideline updates, and the cardiology event of the year. CardioAdvocate will cover what matters most.
ConferenceNegotiated prices for 15 drugs — including Ozempic and Wegovy — go live for Medicare. The biggest test yet of whether price negotiation changes prescribing.
PolicyEMA, UK, and Swiss regulatory decisions expected for the first viable CETP inhibitor. If approved, Germany and UK launches could follow in Q4. US timeline hinges on PREVAIL outcomes.
RegulatoryTwo trials that could reshape treatment: obicetrapib's CV outcomes study and tirzepatide's obesity-mortality trial. Both readouts anticipated next year.
Trial Watch
The most significant U.S. lipid update in over a decade. Absolute LDL-C goals are back. Universal Lp(a) screening is now Class I. Every CardioAdvocate Phenotype article reflects these changes.
Read our editorial →Severe obesity causes a specific molecular lesion in the heart's contractile machinery — and GLP-1 RA-driven weight loss reverses it. This redefines the "obese phenotype" of HFpEF.
HFpEF Phenotype → Obesity Phenotype →The first large-scale trial showing PCSK9 inhibitor benefit in primary prevention: 25% MACE reduction, 36% MI reduction. The era of waiting for an event before using these drugs may be over.
FH Phenotype → Guidelines Phenotype →A 4-part investigative series on the real forces driving American healthcare costs — from PBM rebate walls and hospital facility fees to private equity and the physician pay myth. Part 1, "The Drug Pricing Machine," is live now. Part 2, "Facility Fees," is coming next.
Insights Explorer | Phenotype Explorer | Start Here
CardioAdvocate helps people understand what matters — and how to speak up about it.
